{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:36:17Z","timestamp":1781649377082,"version":"3.54.5"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe alopecia areata in children is difficult to treat, and conventional therapies often show limited efficacy and substantial adverse effects. Dupilumab has shown potential in patients with alopecia areata and an atopic background, and baseline IgE has been proposed as a predictor of response. However, long-term outcomes and maintenance strategies in children with very high IgE levels remain insufficiently described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 7-year-old girl with severe alopecia areata (SALT score 95) and a disease d uration of more than 2 years who had responded poorly to previous glucocorticoid therapy. She had a history of atopic dermatitis (AD), and her serum total IgE level was 2300 IU\/mL. She received dupilumab 300 mg subcutaneously every 4 weeks in combination with topical corticosteroids and, later, topical minoxidil. Hair regrowth was observed after 8 weeks. The SALT score decreased to 5 at week 30, and complete remission was achieved at week 48 (SALT score 0). Serum total IgE decreased in parallel to 330 IU\/mL. After near-complete response, the dosing interval was successfully extended to 6 weeks, and efficacy was maintained through week 48. The only adverse event was a transient mild allergic reaction after the first injection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A progressive reduction in serum total IgE levels was observed in parallel with the patient\u2019s clinical improvement. This case supports dupilumab as a potentially effective and well-tolerated option for severe pediatric alopecia areata in the setting of markedly elevated baseline IgE. It also suggests that dynamic monitoring of\u200b IgE levels may be clinically informative and that interval extension during maintenance therapy may be feasible after a robust response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1832906","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:28Z","timestamp":1777613728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE"],"prefix":"10.3389","volume":"17","author":[{"given":"Zexin","family":"Zhao","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liancheng","family":"Guan","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deping","family":"Luo","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Guizhou University of Traditional Chinese Medicine","place":["Guiyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17187","article-title":"Therapeutic management in paediatric alopecia areata: a systematic review","volume":"35","author":"Wa\u015bkiel-Burnat","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000466704","article-title":"Bullying and quality of life in pediatric alopecia areata","volume":"3","author":"Christensen","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life among patients with alopecia areata: a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.16761\/j.cnki.1000-4963.2020.02.002","article-title":"Chinese guidelines for the diagnosis and treatment of alopecia areata (2019)","volume":"49","year":"2020","journal-title":"J Clin Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.077","article-title":"Treatment of pediatric alopecia areata: a systematic review","volume":"86","author":"Barton","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2174\/1573396316666200430084825","article-title":"Pediatric alopecia areata","volume":"17","author":"Afford","year":"2021","journal-title":"Curr Pediatr Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12578","article-title":"High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata","volume":"32","author":"Smith","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/all.15561","article-title":"Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata","volume":"78","author":"Renert-Yuval","year":"2023","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.031","article-title":"Association between alopecia areata and atopic dermatitis: a nested case-control study of the All of Us database","volume":"90","author":"Diaz","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"B12","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1253795","article-title":"Case report: dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib","volume":"10","author":"Cai","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2312245","DOI":"10.1080\/09546634.2024.2312245","article-title":"Dupilumab therapy for alopecia areata: a case series and review of the literature","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1517769","article-title":"Case report: severe ophiasis-pattern alopecia areata with concomitant atopic dermatitis in a 5-year-old boy successfully treated with dupilumab","volume":"13","author":"Wei","year":"2025","journal-title":"Front Pediatr"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15691","article-title":"Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: a scoping review","volume":"41","author":"Metko","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2976","article-title":"Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab","volume":"154","author":"Penzi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000517832","article-title":"Remission of alopecia universalis after 1 year of treatment with dupilumab in a patient with severe atopic dermatitis","volume":"8","author":"Romagnuolo","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4857510","DOI":"10.1155\/dth\/4857510","article-title":"Long-term dupilumab efficacy and safety in pediatric patients: A real-world experience over 2 years[J","volume":"2025","author":"Traini","year":"2025","journal-title":"Dermatologic Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1203475421995186","article-title":"Alopecia areata related paradoxical reactions in patients on dupilumab therapy: A systematic review","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:30Z","timestamp":1777613730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1832906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1832906"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1832906","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1832906"}}